LSHC

Deloitte Expands Quartz AI™ Suite with Atlas AI™ for Drug Discovery

Retrieved on: 
Montag, Januar 8, 2024
Quartz, Atlas, Drug discovery, Human voice, Synthetic media, Research, Acquisition, API, LSHC, Nvidia Omniverse, AI, Generative, Patient, NVIDIA, Personalized medicine, Medical device

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Today, Deloitte announced Atlas AI™, the latest addition to its Quartz AI™ suite of cross-industry solutions built on the NVIDIA AI and NVIDIA Omniverse™ platforms. As the first life sciences and health care (LSHC) offering under Quartz, Atlas AI includes a novel drug discovery accelerator that helps expedite research and bring new drugs to market faster. By using Generative AI models made accessible with BioNeMo, knowledge representation and reasoning, and custom protein Large Language Models (LLMs) and chemoinformatics LLMs, Atlas AI advances digital biology and transforms drug discovery with the latest AI technologies.

Key Points: 
  • NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Today, Deloitte announced Atlas AI™, the latest addition to its Quartz AI ™ suite of cross-industry solutions built on the NVIDIA AI and NVIDIA Omniverse ™ platforms.
  • As the first life sciences and health care (LSHC) offering under Quartz, Atlas AI includes a novel drug discovery accelerator that helps expedite research and bring new drugs to market faster.
  • By using Generative AI models made accessible with BioNeMo, knowledge representation and reasoning, and custom protein Large Language Models (LLMs) and chemoinformatics LLMs, Atlas AI advances digital biology and transforms drug discovery with the latest AI technologies.
  • Built by the molecular modeling and drug discovery team at Deloitte, recently strengthened by the acquisition of SFL Scientific , Atlas AI also leverages the NVIDIA Omniverse platform, which provides an immersive, collaborative 3D environment for scientists to simulate drug discovery experiments.

Silicon Valley Bank Names Jennifer Friel Goldstein Head of Business Development for Life Science and Healthcare Banking

Retrieved on: 
Mittwoch, Oktober 18, 2023
San Francisco Bay Area, Silicon, Bain, Biotechnology, Working, Bain & Company, First Citizens BancShares, Business development, University, MBA, LSHC, Wharton School of the University of Pennsylvania, Pfizer, SVB, Most, Silicon Valley Bank, Widener University Commonwealth Law School, VC, Investment, College of Engineering (KNUST), SAN, Management, Health care

SAN FRANCISCO, Oct. 18, 2023 /PRNewswire/ -- Silicon Valley Bank (SVB), a division of First Citizens Bank, today announced that 20-year healthcare financing industry veteran Jennifer Friel Goldstein has been appointed Head of Business Development and Strategic Initiatives for Life Science and Healthcare (LSHC) banking. Based in the Bay Area, Goldstein reports to 30-year SVB leader Joan Parsons, Head of Technology and Healthcare Banking.

Key Points: 
  • SAN FRANCISCO, Oct. 18, 2023 /PRNewswire/ -- Silicon Valley Bank (SVB), a division of First Citizens Bank, today announced that 20-year healthcare financing industry veteran Jennifer Friel Goldstein has been appointed Head of Business Development and Strategic Initiatives for Life Science and Healthcare (LSHC) banking.
  • Based in the Bay Area, Goldstein reports to 30-year SVB leader Joan Parsons, Head of Technology and Healthcare Banking.
  • Through its nationwide Life Science and Healthcare practice , SVB provides specialized banking services, debt-financing solutions, industry partnerships, and leading market insights to companies and investors across these sectors.
  • Working closely with SVB's Life Science and Healthcare leadership team, Goldstein will identify market opportunities to connect VC and industry stakeholders to SVB's clients and prospects.

Deloitte AI Institute's New Generative AI Dossier Reveals Key Business-ready Use Cases for Generative AI Deployment

Retrieved on: 
Dienstag, September 12, 2023
Cloud, Workforce, ER, Human, GPS, LSHC, Telecommunications, Synthetic media, Policy, TMT, FSI, Foundation models, Government, Creativity, Organization, Trust, Collection, Patient, NVIDIA, Risk, Google Cloud, Generative, Growth, Ecosystem, AI, AWS, Sales, Medical device, Data

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Today, the Deloitte AI Institute™ unveiled a new report exploring Generative AI use cases across six major industry verticals. With a remarkable capacity to consume and generate information in different modalities, Generative AI has unleashed new ways of working and transforming enterprises across every sector. Amid the current frenzy of advancement and adoption, "The Generative AI Dossier" details 60 of the most compelling use cases for businesses today, serving as a roadmap for executives looking to deploy high-impact Generative AI solutions at scale.

Key Points: 
  • NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Today, the Deloitte AI Institute™ unveiled a new report exploring Generative AI use cases across six major industry verticals.
  • 'The Generative AI Dossier' serves as a guide for leaders looking to do just that.
  • Through its AI Academy™, Deloitte is on the pathway of training up to 10,000 Deloitte practitioners across the globe, using tailored Generative AI training curricula.
  • "The Generative AI Dossier" comes on the heels of recent expansions with key alliances to help Deloitte clients build innovative new AI applications, including Google Cloud and AWS , and NVIDIA .